A phase III trial has shown that patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy.
The IMPRESS trial presented at the ESMO 2014 Congress is a randomised phase III study that compared continuation of gefitinib in addition to chemotherapy against chemotherapy alone in patients with lung cancer that carried mutations in the EGFR cell surface receptor....
A phase III trial has shown that patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy.
The IMPRESS trial presented at the ESMO 2014 Congress is a randomised phase III study that compared continuation of gefitinib in addition to chemotherapy against chemotherapy alone in patients with lung cancer that carried mutations in the EGFR cell surface receptor....